Download
long term therapeutic success of etravirine in switch and naive patients n.
Skip this Video
Loading SlideShow in 5 Seconds..
Long Term Therapeutic Success of Etravirine in Switch and Naive Patients PowerPoint Presentation
Download Presentation
Long Term Therapeutic Success of Etravirine in Switch and Naive Patients

Long Term Therapeutic Success of Etravirine in Switch and Naive Patients

98 Views Download Presentation
Download Presentation

Long Term Therapeutic Success of Etravirine in Switch and Naive Patients

- - - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript

  1. Long Term Therapeutic Success of Etravirine in Switch and Naive Patients L.Bull, M.Bower, M.Nelson Chelsea and Westminster Hospital, London

  2. Background: • Etravirineis a second-generation non-nucleoside reverse transcriptase inhibitor (NNRTI)  • Effective in naïve and switch in those experiencing toxicity to efavirenz1.2 • Low toxicity • Once daily • Potential alternative to other first line third agents • Gazzardet al, AIDS, Nov2011. • Waters et al, AIDS, Jan 2011 2. Waters et al, AIDS, Jan 2011

  3. Methods: • Retrospective case review of all individuals receiving Etravirine with a two nucleos(t)ide backbone • August 2008 and December 2012

  4. Results N=389 345 VL<50 copies/ml 44 VL l>50 copies/m • Median CD4 505cells/mm3 Median CD4 count 300cells/mm3 • Range 137-1480 cells/mm3Range 31-701cells/mm3 • Median VL 44296 copies/ml • Range 508-1819837 copies/ml

  5. Switch Patients with an Undetectable Viral Load - Previous Third Agent N=345

  6. Reasons For Switch

  7. Reasons For Switch 12 from NRTIS: peripheral neuropathy, lipoatrophy ,nausea, transaminitis 7 from raltegravir : transaminitis, peripheral neuropathy, fatigue, poor sleep, depression 3 from nevirapine-nausea, depression, transaminitis 2 from rilpivirine: nausea 4 unknown

  8. Virological Control

  9. Virological Control: All patients with detectable viral loads were non compliant

  10. Reasons for Cessation of Etravirine 86 patients stopped Etravirine Toxicity 76 patients Drug Interactions 6 patients Virological failure 4 patients Chemotherapy 3 Hepatitis C Rx 3

  11. Mean Lipid Values Before and After Treatment with Etravirine

  12. Mean Lipid Values Before and After Treatment with Etravirine 4.93 4.54 P<0.0001* 4.68 4.42 P=0.002* 3.09 2.79 P=0.0001* 1.76 1.48 P<0.0001* 1.14 1.09 P=0.03*

  13. Switch with a Detectable Viral Load (>40 copies/ml) -Previous Third Agent, N=44 9 patients were naïve to therapy. Of the 35 others, median time on their previous regimen was 9 months (range 1 month to 9 years)

  14. Reasons Patients had VL>40 • 20 patients were restarting therapy after Rx break (compliance/ADR/toxicity) • 13 were switched from efavirenz with decreasing viral load with CNS side effects • 9 patients were ARV naïve • 2 patients switched from PI monotherapy with resistance

  15. Reasons for Switch

  16. Virological Control • 27/44 fully suppressed their viral load on etravirine • Remained suppressed for a median of 1 year (range three months to 3 years). • Median CD4 count at 6 months was 417cells/mm3 (range 340-493).

  17. Naïve Patients • All naïve patients suppressed their viral load within 6/12, 3 later stopped etravirine after a mean of 16 months due to: • Heartburn • X2 drug interactions (chemotherapy/hepatitis c) • The other 6 have remained undetectable for median of 2 years (range 6 months to 3 years)

  18. Reasons for Cessation of Etravirine 17 patients switched from etravirine All viraemic patients were non compliant with medication

  19. Virological Failure All patients non compliant, 4 develop ETR mutations

  20. Conclusions • Etravirine is an alternative switch option in individuals with an undetectable viral load and intolerant of their current third agent • Only one individual switching with an undetectable viral load developed resistance to ETR over a total follow up of 803 patients years • Switching to etravirine resulted in improvements in total cholesterol, LDL and TGs • Limited data available in individuals naïve to therapy and further data is required